Abbott Laboratories’ (ABT) Overweight Rating Reaffirmed at Piper Sandler

Abbott Laboratories (NYSE:ABT)‘s stock had its “overweight” rating reissued by equities researchers at Piper Sandler in a report released on Friday,Benzinga reports. They currently have a $118.00 price target on the healthcare product maker’s stock, up from their prior price target of $115.00. Piper Sandler’s price target would indicate a potential upside of 18.25% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Barclays decreased their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. Benchmark cut their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Oppenheimer lowered their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Leerink Partners dropped their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.43.

Abbott Laboratories Stock Up 1.0%

ABT traded up $0.96 during trading on Friday, hitting $99.79. The stock had a trading volume of 11,737,314 shares, compared to its average volume of 12,345,983. The stock has a 50 day simple moving average of $89.56 and a two-hundred day simple moving average of $102.18. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a market capitalization of $173.82 billion, a PE ratio of 27.92, a PEG ratio of 1.54 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp boosted its stake in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after acquiring an additional 1,627,791 shares during the last quarter. Capital International Investors increased its position in shares of Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP raised its stake in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in shares of Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: JPMorgan raised its price target on Abbott to $120 and kept an overweight rating, signaling confidence in additional upside. JPMorgan raises Abbott price target
• Positive Sentiment: Wells Fargo lifted its target to $112 and maintained an overweight rating, while TD Cowen and RBC also reiterated bullish calls, adding to the positive analyst tone. Analysts raise Abbott forecasts after Q2 results
• Positive Sentiment: Abbott’s Q2 results topped expectations and the company raised full-year EPS guidance, with management highlighting stronger second-half demand across key businesses. Abbott reports Q2 2026 results and raises guidance
• Positive Sentiment: Analysts and market commentary said the better-than-expected quarter eased concerns and helped the stock regain Wall Street confidence, with particular strength in medical devices and diagnostics. Abbott stock winning back Wall Street
• Neutral Sentiment: Some articles noted that Abbott’s profit fell year over year in Q2 despite better sales, reflecting margin and mix changes rather than a clear operational setback. WSJ report on Abbott Q2

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.